Merck stock trades steadily as Keytruda revenue supports earnings

Merck stock is underpinned by strong oncology revenue, with Keytruda continuing to drive double?digit growth and supporting the group’s earnings profile despite upcoming patent expirations.

Merck & Co., Inc. (ISIN US58933Y1055) stock remains supported by its leading oncology franchise, as recent quarterly figures highlight how revenue from immuno?oncology drug Keytruda continues to underpin the company’s earnings profile. According to the company’s latest reported quarter in 2024, Merck generated roughly $60 billion in total revenue for fiscal 2023, with oncology treatments and vaccines accounting for a substantial share of the top line. The numbers show that Merck’s portfolio, led by Keytruda, continues to deliver growth even as investors watch the approaching loss of exclusivity for several key products.

Keytruda revenue above $25 billion

A central metric for Merck stock is the performance of its flagship cancer drug Keytruda, which has become one of the world’s largest prescription medicines by sales. In fiscal 2023, Merck reported that Keytruda revenue was more than $25 billion, reflecting continued uptake in indications such as lung cancer, melanoma, and other solid tumors. This represented a double?digit increase versus the prior year, as Keytruda revenue in 2022 was in the low?$20?billion range, highlighting growth of several billion dollars year on year and demonstrating that oncology remains Merck’s most important earnings driver. Investors in Merck stock closely monitor this trajectory because Keytruda’s patent protection is scheduled to phase out toward the end of this decade, which will eventually expose the product to biosimilar competition.

Beyond Keytruda, Merck’s human health segment includes vaccines and hospital products that contribute additional volume and margin. For example, the company’s pneumococcal vaccine franchise and human papillomavirus (HPV) vaccine Gardasil have seen strong demand, with vaccine revenue contributing several billion dollars annually to Merck’s total sales base. In fiscal 2023, vaccine sales were reported in the high single?digit billions of dollars, up versus 2022, and providing diversification relative to the oncology franchise. This segment mix gives Merck stock a foundation of cash flow across different therapeutic areas, which can be reinvested into research and development.

Revenue growth compared with prior year

Merck’s recent earnings releases emphasize that overall company revenue has expanded compared with the prior year, even after adjusting for the impact of certain one?time items and the company’s former COVID?19 antiviral sales. For fiscal 2023, Merck reported total revenue of about $60 billion, up from roughly the mid?$50?billion range in 2022, equivalent to an increase on the order of 8% to 10% year on year. This growth was driven primarily by Keytruda and vaccines, partially offset by declining sales of COVID?19 treatments as pandemic?related demand faded. Operating income and earnings per share also improved, with Merck reporting non?GAAP EPS in the mid?$7 range for 2023 compared with the mid?$6 range in 2022, signaling that the company translated top?line growth into bottom?line gains.

For investors analyzing Merck stock, the comparison of 2023 and 2022 revenue highlights the company’s ability to generate growth in its core franchise despite external pressures such as pricing dynamics and competition. The double?digit growth in Keytruda revenue reflects expanded use in earlier?stage disease and combinations, while vaccines benefited from increased awareness and catch?up immunization. This combination allowed Merck to raise its guidance during the course of the year, and by the time full?year results were reported, the company had delivered revenue at the upper end of the guided range, underscoring execution quality.

Looking ahead, consensus estimates for fiscal 2024 generally project that Merck will deliver another year of revenue growth, with total sales expected to edge higher into the low?$60?billion area and non?GAAP EPS to trend upward from the prior year. Keytruda is forecast to continue its expansion, with revenue that could approach the high?$20?billion range, while vaccine sales are expected to grow modestly. However, investors are aware that over time, Merck will need new products to offset eventual Keytruda patent expirations, which is why the company’s investment in pipeline assets and business development deals is closely scrutinized.

Pipeline and business development

Merck has been actively investing in its research pipeline and pursuing targeted acquisitions to diversify beyond Keytruda and sustain growth post?patent expiry. Over recent years the company has announced multiple licensing deals and smaller bolt?on acquisitions in oncology, cardiometabolic disease, and immunology. The goal is to build a portfolio of next?generation therapies that can complement or succeed current blockbusters. Merck’s R&D budget reflects this focus, with annual research and development expenses exceeding $10 billion in fiscal 2023, up from around $9 billion in 2022, underlining a commitment to innovation and clinical development across several late?stage assets.

Among pipeline highlights frequently discussed by analysts are Merck’s investigational therapies in oncology that seek to build on the immune checkpoint inhibition mechanism pioneered by Keytruda. The company is evaluating combinations of Keytruda with other agents, as well as novel molecules in different pathways that could extend the reach of immuno?oncology. In addition, Merck is developing drugs in cardiovascular and metabolic indications, which could offer diversification into large patient populations beyond cancer. For investors, these programs are relevant because successful clinical outcomes could generate new multi?billion?dollar franchises and thereby support Merck stock valuation when Keytruda exclusivity wanes.

Merck also maintains a significant vaccines pipeline, including candidates targeting respiratory syncytial virus (RSV) and other pathogens. Vaccine development is capital intensive and subject to regulatory scrutiny, but it can result in durable revenue streams if products achieve broad uptake. Merck’s history with Gardasil and its other prophylactic vaccines suggests that the company has operational experience in large?scale manufacturing and distribution, which is an asset when launching new vaccines. Analysts often compare Merck’s vaccine strategy with that of peers such as Pfizer and GSK, noting differences in focus areas and timing, which can influence competitive positioning in segments like RSV.

Operating margin and cash flow strength

Merck’s earnings reports show that the company has maintained solid operating margins despite rising R&D investment. In fiscal 2023, Merck reported an operating margin in the mid?20% range, slightly higher than in 2022, supported by favorable product mix and disciplined cost management. Gross margin remained robust in oncology due to the high value of Keytruda therapy, while vaccines and hospital products provided a diversified margin profile. This margin performance matters for Merck stock because it indicates the company’s ability to fund innovation and shareholder returns without compromising financial stability.

Free cash flow is another key metric underpinning Merck’s financial flexibility. In 2023, Merck generated free cash flow in the tens of billions of dollars, sufficient to cover R&D spending, dividends, and share repurchases. The company has a track record of paying regular dividends, with the annual dividend per share in the low?$3 area for 2023, up from the high?$2 range in prior years, supporting income?oriented investors. Merck’s balance sheet shows manageable net debt relative to EBITDA, which allows the company to pursue business development and acquisitions when strategic opportunities arise.

The combination of strong operating margin, significant free cash flow, and a predictable dividend stream has made Merck stock attractive for investors seeking exposure to large?cap pharma with a mix of growth and income characteristics. At the same time, valuation is influenced by the timeline for Keytruda patent expiry and the perceived strength of the pipeline. If late?stage assets deliver positive clinical data, the market may assign higher value to Merck’s future earnings, offsetting concerns about exclusivity loss.

Keytruda leads Merck oncology

Keytruda’s role in Merck’s portfolio extends beyond revenue. The drug has become a platform for combination therapies and earlier?line treatment strategies, which can expand its patient reach and prolong its lifecycle. Merck has secured approvals for Keytruda in multiple indications, making it a standard of care in various tumor types. This breadth of approval has helped drive the more than $25 billion in 2023 revenue, and the company continues to invest in clinical trials to explore new uses, including adjuvant and neoadjuvant settings.

In many markets, Keytruda competes with other checkpoint inhibitors, including pembrolizumab’s class peers, but its clinical data and label breadth have allowed Merck to capture a leading share of the segment. Pricing and reimbursement differences across geographies affect realized revenue, yet the overall global oncology franchise has proven resilient. Analysts frequently point out that Merck’s dependence on Keytruda is a double?edged sword: the product’s success provides strong earnings support, but it also concentrates risk if competitive dynamics or regulatory changes alter the market structure.

Merck is working to mitigate this concentration by building complementary oncology assets around Keytruda. These include therapies targeting different pathways, combination regimens, and next?generation antibodies. If these efforts succeed, Merck could transition from a single?blockbuster?driven oncology portfolio to a more diversified suite of cancer treatments. That would be important for Merck stock valuation after Keytruda’s patents expire, because investors would have greater confidence in the sustainability of oncology earnings.

Vaccines and other segments

While oncology captures much of the attention, Merck’s vaccine business also plays a key role in its financial profile. Gardasil, the company’s HPV vaccine, remains a major contributor to revenue, with sales in the multi?billion?dollar range for 2023 and growth versus 2022. Demand is driven by public?health programs and increased awareness of HPV?related cancers. This vaccine revenue is typically less volatile than certain specialty?care drugs, providing a stabilizing effect on Merck’s overall sales mix.

Merck’s portfolio includes additional vaccines and medicines in hospital acute care, diabetes, and other therapeutic areas. These products may not individually match Keytruda’s scale, but collectively they add meaningful revenue. For example, Merck’s diabetes medications have generated revenue in the low?billion?dollar range annually, while hospital acute care products contribute hundreds of millions of dollars. This diversification means that even as the company leans heavily on oncology, it still benefits from multiple income streams, which is relevant for Merck stock holders assessing resilience against therapeutic?area specific shocks.

In animal health, Merck operates a global business providing vaccines and pharmaceuticals for livestock and companion animals. Animal health revenue reached several billion dollars in 2023, with modest growth compared with 2022. Though smaller than human health, the segment offers steady cash flow and exposure to different economic drivers, including agriculture and pet ownership trends. Some investors view animal health as a defensive element within Merck’s portfolio, adding non?correlated revenue within the broader healthcare space.

Comparisons with large pharma peers

Merck shares several characteristics with other large?cap pharmaceutical companies such as Pfizer, Bristol Myers Squibb, and Johnson & Johnson, including a balance of mature products and late?stage pipeline assets. However, the scale and concentration of Keytruda revenue distinguish Merck from peers whose oncology portfolios are more diversified across several drugs. For example, while some competitors have multiple oncology products each generating several billion dollars in annual sales, Merck’s oncology earnings are more heavily tilted toward a single blockbuster. This can lead to different valuation dynamics, with Merck stock sometimes trading at a discount or premium depending on investor confidence in its pipeline.

Analysts tracking large pharma often compare Merck’s research spending with that of peers. In 2023, Merck’s R&D budget exceeded $10 billion, comparable to or higher than some competitors on an absolute basis, though similar on a percentage?of?sales basis. This level of investment is seen as necessary to maintain a competitive edge in oncology, vaccines, and other growth areas. It reflects an industry environment in which innovation is critical to offset patent expirations and pricing pressure.

From an earnings perspective, Merck’s non?GAAP EPS in the mid?$7 range for 2023 positions it among the more profitable large pharma companies. Some peers reported similar or higher EPS figures, depending on their product mix and one?time items, but Merck’s combination of revenue growth and margin stability has been viewed favorably. The company’s dividend policy further shapes investor perception, as a rising dividend backed by strong cash flow can be appealing for long?term holders in the sector.

Merck revenue up around 8 percent

The headline comparison that many investors focus on is Merck’s revenue growth trajectory. Between fiscal 2022 and fiscal 2023, total revenue increased from roughly the mid?$50?billion range to about $60 billion, which corresponds to an increase on the order of 8% to 10%. This growth rate is noteworthy in the context of large?cap pharma, where patent expirations and pricing pressures often limit top?line expansion. Merck’s ability to deliver high?single?digit to low?double?digit growth, driven mainly by Keytruda and vaccines, underpins positive sentiment toward Merck stock.

Within this growth, the more than $25 billion in Keytruda revenue for 2023 compared with the low?$20?billion range in 2022 implies a revenue increase of several billion dollars for the oncology franchise year on year. This is a key quantified comparison: it shows that while other parts of the business may grow more modestly, Keytruda alone adds enough incremental sales to move the needle on Merck’s total revenue. Vaccine revenue also grew compared with 2022, though at a lower absolute scale, contributing to the overall expansion.

Merck’s non?GAAP EPS growth from the mid?$6 range in 2022 to the mid?$7 range in 2023 similarly demonstrates earnings leverage. The company’s operating margin in the mid?20% range and disciplined cost control allowed incremental revenue to fall through to the bottom line. For Merck stock, this earnings trajectory is important because it affects valuation multiples such as price?to?earnings and enterprise?value?to?EBITDA, which investors use to benchmark large pharma names.

Keytruda supports Merck revenue

Merck’s flagship product Keytruda is a humanized monoclonal antibody that targets the PD?1 receptor, enhancing the immune system’s ability to detect and destroy cancer cells. Its role in Merck’s revenue is pivotal: with more than $25 billion in sales for 2023, Keytruda accounts for a large share of the company’s human health revenue. In several oncology indications, Keytruda has achieved category?leading status, which provides Merck with pricing power and strong demand visibility.

Keytruda’s approval in multiple lines of therapy and across tumor types has allowed Merck to expand its market. For instance, in non?small cell lung cancer, Keytruda is approved as monotherapy and in combination with chemotherapy, while in melanoma and other cancers it is used in both metastatic and early?stage settings. This range of uses helps sustain high levels of revenue and supports Merck’s strategy of investing in combination trials that may further differentiate the drug from competitors.

From a business perspective, Keytruda’s success gives Merck the financial resources to invest in new areas. The company’s R&D spending of over $10 billion in 2023, an increase versus 2022, is partially funded by blockbuster earnings from Keytruda and vaccines. If new therapies emerging from this investment achieve approval and commercial success, they could gradually reduce Merck’s reliance on Keytruda while preserving a strong oncology presence.

Merck stock and current valuation

Merck stock is listed on the New York Stock Exchange under the symbol MRK and is a constituent of the S&P 500 index, placing it among the largest and most followed companies on the US market. As of a recent trading day in mid?2026, Merck shares traded in the mid?$120 range, giving the company a market capitalization in the low?$300?billion area. This valuation reflects investor expectations for continued earnings support from Keytruda and vaccines, as well as confidence in Merck’s ability to develop new products to offset future patent expirations.

The share price in the mid?$120 range positions Merck stock close to its 52?week highs, which are also in the $120s. Over the past year, the stock has delivered positive total returns, including price appreciation and dividends. Merck’s price?to?earnings ratio based on forward earnings estimates sits in the high?teens to low?twenties, broadly in line with or slightly above some large?cap pharma peers, indicating that the market assigns a premium for Merck’s oncology leadership and pipeline prospects.

Liquidity in Merck stock is high, with millions of shares traded daily on NYSE. This makes it relatively straightforward for institutional and retail investors to enter or exit positions. Options liquidity also allows for various hedging and yield?enhancement strategies. For long?term investors, the combination of a sizable dividend, large market capitalization, and inclusion in major indices like the S&P 500 can make Merck a core holding in diversified healthcare portfolios.

Fact box: Merck & Co., Inc.

Merck & Co. key data

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: NYSE: MRK
• Trading venue: NYSE
• Price (as of 23 July 2026, 02:00 UTC): 124.00 USD
• Market capitalization: 315,000,000,000 USD (as of 23 July 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: 30 July 2026